Insulin therapy in patients with type 2 diabetes and high insulin resistance is associated with increased risk of complications and mortality

References

• American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13–S28.
   PubMedGoogle Scholar
• Connor T, Martin SD, Howlett KF, et al. Metabolic remodelling in obesity and type 2 diabetes: pathological or protective mechanisms in response to nutrient excess? Clin Exp Pharmacol Physiol. 2015;42(1):109–115.
   PubMed Web of Science ®Google Scholar
• Schwartz SS, Epstein S, Corkey BE, et al. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification schema. Diabetes Care. 2016;39(2):179–186.
   PubMed Web of Science ®Google Scholar
• Taylor R. Insulin resistance and type 2 diabetes. Diabetes. 2012;61:778–779.
   PubMed Web of Science ®Google Scholar
• Halban PA, Polonsky KS, Bowden DW, et al. beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab. 2014;99(6):1983–1992.
   PubMed Web of Science ®Google Scholar
• Weyer C, Tataranni PA, Bogardus C, et al. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24(1):89–94.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90–S102.
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet (London, England). 1998;352(9131):854–865.
   Google Scholar
• Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–328.
   PubMed Web of Science ®Google Scholar
• Akalin S, Berntorp K, Ceriello A, et al. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the global task force on glycaemic control. Int J Clin Pract. 2009;63(10):1421–1425.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
   PubMed Web of Science ®Google Scholar
• Genuth S, Ismail-Beigi F. Clinical implications of the ACCORD trial. J Clin Endocrinol Metab. 2012;97(1):41–48.
   PubMed Web of Science ®Google Scholar
• Faghihi-Kashani S, Bonnet F, Hafezi-Nejad N, et al. Fasting hyperinsulinaemia and 2-h glycaemia predict coronary heart disease in patients with type 2 diabetes. Diabetes Metab. 2016;42(1):55–61.
   PubMed Web of Science ®Google Scholar
• Lakka HM, Lakka TA, Tuomilehto J, et al. Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Internal Med. 2000;160(8):1160–1168.
   PubMedGoogle Scholar
• Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 2003;88(6):2399–2403.
   PubMed Web of Science ®Google Scholar
• Nolan CJ, Ruderman NB, Kahn SE, et al. Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes. 2015;64(3):673–686.
   PubMed Web of Science ®Google Scholar
• Taegtmeyer H, Beauloye C, Harmancey R, et al. Insulin resistance protects the heart from fuel overload in dysregulated metabolic states. Am J Physiol Heart Circ Physiol. 2013;305(12):H1693–7.
   PubMed Web of Science ®Google Scholar
• Schwartz SS, Jellinger PS, Herman ME. Obviating much of the need for insulin therapy in type 2 diabetes mellitus: a re-assessment of insulin therapy’s safety profile. Postgrad Med. 2016;128(6):609–619.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani M, DeFronzo RA. Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm. Diabetes Care. 2017;40(8):1121–1127.
   PubMed Web of Science ®Google Scholar
• (CDC) CfDCaP, (NCHS) NCfHS. The National Health and Nutritional Examination Survey (NHANES): sample design, 1999–2006. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2012.
   Google Scholar
• (CDC) CfDCaP, (NCHS) NCfHS. National health and nutrition examination survey data. Hyattsville (MD): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2001–2010.
   Google Scholar
• (CDC) CfDCaP, (NCHS). NCfHS. National health and nutrition examination laboratory protocol. Hyattsville (MD): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2015.
   Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–1495.
   PubMed Web of Science ®Google Scholar
• Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5(4):673–682.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services CfD, Control and Prevention NCfHS. Reference manuals and reports: analytic guidelines 1999–2010. Hyattsvilee (MD): National Center for Health Statistics; 2013.
   Google Scholar
• Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf. 2008;17(8):753–759.
   PubMed Web of Science ®Google Scholar
• Colayco DC, Niu F, McCombs JS, et al. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care. 2011;34(1):77–83.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Evans M, et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013;98(2):668–677.
   PubMed Web of Science ®Google Scholar
• Hsu PF, Sung SH, Cheng HM, et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study. Diabetes Care. 2013;36(4):894–900.
   PubMed Web of Science ®Google Scholar
• Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation. 2011;123(3):342–348.
   PubMed Web of Science ®Google Scholar
• Moheet A, Seaquist ER. Hypoglycemia as a driver of cardiovascular risk in diabetes. Curr Atheroscler Rep. 2013;15(9):351.
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study (UKPDS). 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310(6972):83–88.
   PubMed Web of Science ®Google Scholar
• Herman ME, O’Keefe JH, Bell DSH, et al. Insulin therapy increases cardiovascular risk in type 2 diabetes. Prog Cardiovasc Dis. 2017;60(3):422–434.
   PubMed Web of Science ®Google Scholar
• Ormazabal V, Nair S, Elfeky O, et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.
   PubMedGoogle Scholar
• Pradhan AD, Everett BM, Cook NR, et al. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA. 2009;302(11):1186–1194.
   PubMed Web of Science ®Google Scholar
• Paneni F, Costantino S, Cosentino F. Insulin resistance, diabetes, and cardiovascular risk. Curr Atheroscler Rep. 2014;16(7):419.
   PubMed Web of Science ®Google Scholar
• Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13:47.
   PubMed Web of Science ®Google Scholar